PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

A major new study reveals that both sugar-sweetened beverages (SSBs) and low- or non-sugar-sweetened beverages (LNSSBs) are significantly associated with a higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD).

2025-10-06
(Press-News.org) Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

(Berlin, Germany, Tuesday, 7 October 2025) A major new study reveals that both sugar-sweetened beverages (SSBs) and low- or non-sugar-sweetened beverages (LNSSBs) are significantly associated with a higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD).1

The study, presented today at UEG Week 2025, followed 123,788 UK Biobank participants without liver disease at baseline. Beverage consumption was assessed using repeated 24-hour dietary questionnaires. Researchers examined the associations between SSB and LNSSB intake and the risks of developing MASLD, liver fat accumulation and liver-related mortality.

A higher intake of both LNSSBs and SSBs (>250g per day) was associated with a 60% (HR: 1.599) and 50% (HR: 1.469) elevated risk of developing MASLD, respectively. Over the median 10.3-year follow-up, 1,178 participants developed MASLD and 108 died from liver-related causes. While no significant association was observed for SSBs, LNSSB consumption was additionally linked to a higher risk of liver-related mortality. Both beverage types were also positively associated with higher liver fat content.

MASLD, formally known as non-alcoholic fatty liver disease (NAFLD), is a condition where fat accumulates in the liver, which overtime can cause inflammation (hepatitis) and symptoms such as pain, fatigue and loss of appetite.2 The disease has emerged as a global health burden since being recognised as the most common chronic liver disease, with experts estimating that it affects over 30% of people worldwide and is a rapidly increasing cause of liver-related deaths.3

Lead author of the study, Lihe Liu, commented, “SSBs have long been under scrutiny, while their ‘diet’ alternatives are often seen as the healthier choice. Both, however, are widely consumed and their effects on liver health have not been well understood.”

“Our study shows that LNSSBs were actually linked to a higher risk of MASLD, even at modest intake levels such as a single can per day. These findings challenge the common perception that these drinks are harmless and highlight the need to reconsider their role in diet and liver health, especially as MASLD emerges as a global health concern.”

Liu noted the potential biological mechanisms that may underlie the observed risks, “The higher sugar content in SSBs can cause rapid spikes in blood glucose and insulin, promote weight gain and increase uric acid levels, all of which contribute to liver fat accumulation. LNSSBs, on the other hand, may affect liver health by altering the gut microbiome, disrupting the feeling of fullness, driving sweet cravings and even stimulating insulin secretion.”

The authors emphasised that these findings support limiting both SSBs and LNSSBs as part of a comprehensive prevention strategy, targeting not only liver disease but also cardio-renal-metabolic health. Replacing either beverage with water significantly reduced MASLD risk – by 12.8% for SSBs and 15.2% for LNSSBs – while substitution between the two types of beverages offered no risk reduction.

Liu added, “The safest approach is to limit both sugar-sweetened and artificially sweetened drinks. Water remains the best choice as it removes the metabolic burden and prevents fat accumulation in the liver, whilst hydrating the body.”

The researchers now aim to explore causal mechanisms more deeply through long-term, randomised and genetic trials with a focus on how sugar and its substitutes interact with the gut microbiome and influence liver disease.

END

Notes to editors:

For further information or to arrange an expert interview, please contact media@ueg.eu

We kindly ask that a reference to UEG Week 2025 is included when communicating any information within this press release.

About the author:

Lihe Liu is a graduate student in the Department of Gastroenterology at the First Affiliated Hospital of Soochow University, Suzhou, China. Her research focuses on metabolic liver diseases and gastroenterology, where she applies data-driven approaches using R and Python to support clinical research.

About UEG:

Founded in 1992, United European Gastroenterology (UEG) is the leading non-profit organisation for excellence in digestive health in Europe and beyond with its headquarters in Vienna. We improve the prevention and care of digestive diseases in Europe through providing top tier education, supporting research and advancing clinical standards.

As Europe’s home and umbrella for multidisciplinary gastroenterology, we unite over 50,000 engaged professionals from national and specialist societies, individual digestive health experts and related scientists from all fields and career stages. Over 30,000 digestive healthcare professionals from around the world have joined the UEG Community as UEG Associates and UEG Young Associates. The UEG Community enables digestive health professionals from across the globe to become UEG Associates and thereby connect, network and benefit from a wide range of free resources and educational activities.

Find out more about UEG’s work by visiting: https://ueg.eu/

References:

Liu, L et al. Sugar- and low/non-sugar-sweetened beverages and risks of metabolic dysfunction-associated steatotic liver disease and liver-related mortality: A prospective analysis of the UK Biobank. Presented at UEG Week 2025; 7 October 2025; Berlin, Germany. Girish, V. and John, S. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). (2025). PMID: 31082077 Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. (2023). Journals. DOI: 10.1097/HEP.0000000000000004 END



ELSE PRESS RELEASES FROM THIS DATE:

Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields

2025-10-06
We often think of plastic pollution as a problem of oceans and seabirds. But beneath our feet, in the quiet dark of agricultural soils, a new kind of contamination is unfolding—one with profound implications for climate, crops, and carbon. A pioneering two-year field study has revealed that biodegradable microplastics, often hailed as eco-friendly alternatives to conventional plastics, are quietly reshaping the chemistry of farmland soils in unexpected and complex ways. Published on August 22, 2025, in Carbon Research as an open-access original article, this research was co-led by Dr. Jie ...

Yeast proteins reveal the secrets of drought resistance

2025-10-06
Our bodies are made up mostly of water. If this water is removed, our cells cannot survive, even when water is reintroduced. But some organisms can completely dry out yet return to life when rehydrated. A new study in Cell Systems helps explain how organisms can come back from desiccation (the removal of water or moisture) while others fail by looking at the cell’s proteins. In the first survey of its kind, a team of researchers profiled thousands of proteins at once for their ability to survive dehydration and ...

Psychiatry, primary care, and OB/GYN subspecialties hit hardest by physician attrition

2025-10-06
Embargoed for release until 5:00 p.m. ET on Monday 6 October 2025    Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin              Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, ...

New Canadian study reveals where HIV hides in different parts of the body

2025-10-06
New Canadian study reveals where HIV hides in different parts of the body Researchers at Western University and the University of Calgary have discovered how HIV hides in different parts of the body by embedding itself into the DNA of cells in a tissue-specific manner, offering new insights into why the virus is so difficult to eliminate and cure – even decades after infection and treatment. The study, led by Western University’s Stephen Barr and UCalgary’s Guido van Marle, reveals that HIV cloaks itself in the DNA of infected cells using unique DNA patterns in the ...

Lidocaine poisonings rise despite overall drop in local anesthetic toxicity

2025-10-06
Over the last decade, poisonings and deaths linked to the use of local anesthetics have decreased. Even so, poisonings from one commonly used anesthetic, lidocaine, have increased in the United States, according to two new studies from the University of Illinois Chicago. By analyzing data from reports to national Poison Control Centers and to the Food and Drug Administration from 2010 to 2020, UIC researchers found total reports of poisonings fell 50% in that period. But poisonings from lidocaine increased more than 50% in less than half that ...

Politics follow you on the road

2025-10-06
Nobody wants to admit that a lowly bumper sticker can influence their behavior. But researchers at the University of Cincinnati found that drivers were far more likely to honk after being cut off by a vehicle bearing a political bumper sticker, particularly one for the opposing political party. “Bumper stickers are a meaningful way in which partisan divides are reinforced in everyday life,” UC researchers concluded. “They have tangible impacts on road safety. Partisan bumper stickers may be mundane, but they are not trivial.” For a study published in the journal Frontiers in Political Science, UC Assistant ...

Scientists blaze new path to fighting viral diseases

2025-10-06
JUPITER, Fla. — In a quest to develop new antiviral drugs for COVID-19 and other diseases, a collaboration led by scientists at The Wertheim UF Scripps Institute has identified a potential new drug against the virus that causes COVID-19. In the process, the team devised a powerful new platform for finding medicines to fight many types of infectious diseases. Writing in the Journal of the American Chemical Society, in an online article posted on Monday, Oct. 6, 2025, the scientists said they began by seeking ...

The mouse eye as a window to spotting systemic disease

2025-10-06
A new method of taking microscopic images of a live mouse’s retina through the eye allows to record the reaction of brain cells to disease and treatment. The Kobe University development is more easily applicable than previous methods and promises to advance research on and treatment of vision-related diseases. Diabetic retinopathy, a form of diabetic eye disease, is one of the leading causes of blindness around the globe. “It’s understood that vision is lost due to damage to the blood vessels in the retina, but recent research has identified that abnormalities in neurons and immune cells begin prior to vascular damage,” says Kobe ...

AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneurs

2025-10-06
Rockville, MD. (October 6, 2025) – The 2025 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship will convene an extraordinary roster of world-renowned scientists, entrepreneurs, investors, and patient advocates on October 24, 2025, at the National Press Club in Washington, D.C. This is a signature annual gathering where the leaders driving the future of oncology come together under one roof to challenge the status quo, reveal bold ideas, share insights, and spark collaborations that shape what’s next in cancer research ...

FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials

2025-10-06
Key takeaways Internal organ tissues often don’t heal after illness or injury and lose some function, such as the heart after a heart attack. UCLA cardiologists have identified a protein that interferes with healing. Funded entirely by federal and state grants, the researchers developed a drug to block this protein and promote tissue regeneration. The FDA has now granted approval to begin Phase I clinical trials of the first-in-class drug for tissue repair, called AD-NP1, in humans. The body’s tissues can get injured in many ways, but while some injuries ...

LAST 30 PRESS RELEASES:

New software tool MARTi fast-tracks identification and response to microbial threats

Rare brain cell may hold the key to preventing schizophrenia symptoms

A new tool to find hidden ‘zombie cells’

New Cleveland Clinic research finds up to 5% of Americans carry genetic mutations associated with cancer risk

Once tadpoles lose lungs, they never get them back

Small group of users drive invasive species awareness on social media

One bad safety review can tank an Airbnb booking — Even among thousands of positive ones, new study finds

Text-based system speeds up hospital discharges to long-term care

California schools are losing tree canopy

How people learn computer programming

Exploring a mechanism of psychedelics

Scientists can now explore mechanisms behind attachment issues

Researchers watched students’ brains as they learned to program

An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program

AI-powered diabetes prevention program shows similar benefits to those led by people

New study may transform diagnosis of Britain’s number one cancer

Stillbirths in the United States

How animals get their spots, and why they are beautifully imperfect

Stillbirths in the U.S. higher than previously reported, often occur with no clinical risk factors

Durability of 2024-2025 COVID-19 vaccines against JN.1 subvariants

Online unsupervised Tai Chi intervention for knee pain and function in people with knee osteoarthritis

A nose for microbes: how hunger tunes the brain

TRF1 protein loss reduces body fat and improves metabolic health in mice without shortening telomeres

JMIR Medical Education invites submissions on bias, diversity, inclusion, and cultural competence in medical education

SwRI receives $9.9 million contract to assess reliability of F-16 landing gear components

Computer scientists build AI tool to spot risky and unenforceable contract terms

Self-affirmations can boost well-being, study finds

New certification helps clinicians advance digital cardiac care

Why earthquakes sometimes still occur in tectonically silent regions

Music therapy during surgery reduces anesthetic use and stress responses

[Press-News.org] Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds
A major new study reveals that both sugar-sweetened beverages (SSBs) and low- or non-sugar-sweetened beverages (LNSSBs) are significantly associated with a higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD).